论文部分内容阅读
目的 探索ICM -DNA定量检测在鉴别良恶性肿瘤诊断中的应用。方法 对 12 1例原先不提供临床病史和病理检查结果的组织切片作改良的DNA染色和ICM -DNA定量检测。结果 (1) 36例无ICM -DNA定量恶性指数的病例中 ,与原先临床及病理结果有 34例相吻合 ,其DNA指数 (DI) 0 .72 - 1.10 ,中位数DI 1.0 ,2倍体 (C)、3- 4C和≥ 5C细胞所占中位数百分比分别为 71.33%、2 6 .2 1%和 0 .98%。 (2 ) 85例有恶性指数与原先临床及病理结果完全一致 ,其DI自 1.2 - 2 .72 ,中位数DI 1.33,2C、3- 4C和 5C细胞所占的中位数百分比分别为 2 9.4 1%、6 2 .6 2 %和4 .76 %。 (3) 85例恶性组的DNA直方图表型为 :近二倍体肿瘤占 14.12 % (12 /85) ,近四倍体肿瘤占 2 .35% (2 /85) ,多倍体肿瘤占 5.88% (5/85)和非整倍体肿瘤 77.6 5% (6 6 /85)。近二倍体肿瘤多为黏膜相关淋巴瘤、高分化癌和低度恶性软组织肉瘤。结论 ICM -DNA定量分析中DI值、倍体分布、异倍体的比例和DNA直方图表型不仅是判别良恶性肿瘤的重要依据 ,而且正确运用内参和外参照校正ICM检测基准 ,合理的定标更是ICM -DNA定量鉴别良恶性肿瘤的关键。
Objective To explore the application of quantitative detection of ICM-DNA in the differential diagnosis of benign and malignant tumors. Methods Tissue sections from 12 1 patients who did not provide clinical history and pathological results were tested for DNA staining and ICM-DNA quantification. Results (1) Of the 36 cases without ICM-DNA quantitative malignant index, there were 34 cases with original clinical and pathological findings with DNA index (DI) of 0.72-1.10, median of DI 1.0, diploid (C), 3 - 4C and ≥ 5C cells accounted for 71.33%, 26.21% and 0.98%, respectively. (2) The malignant index in 85 cases was completely consistent with the original clinical and pathological findings. The median percentage of DI from 1.2 to 2.72, median DI 1.33, 2C, 3 to 4C and 5C were 2 9.4 1%, 62.2% and 4.76% respectively. (3) The DNA histogram phenotypes of 85 malignant groups were nearly diploid (14.12%), nearly tetraploid (2.35%), polyploid % (5/85) and aneuploidy tumors 77.6 5% (66/85). Nearly diploid tumors are mostly mucosa-associated lymphoma, well-differentiated carcinoma and low-grade soft tissue sarcoma. Conclusions DI value, ploidy distribution, aneuploid ratio and DNA histogram phenotype in quantitative analysis of ICM-DNA are not only the important basis for judging benign and malignant tumors, but also correct the ICM detection standard by internal and external reference, It is the key to quantitatively identify benign and malignant tumors with ICM-DNA.